In order to modulate some of the main pathological manifestations induced by DM1, we have designed and synthesized a novel family of 4-arylthioalkyl-1-carboxyalkyl-1,2,3-triazoles (MP compounds) capable of normalizing the FKBP12/RyR1 interaction and modulating calcium dysregulation under oxidative stress conditions [21,46] to further evaluate their impact in experimental models of DM1 disease. This evidence concerns the gene FKBP1A and myotonic dystrophy type 1.